CD200 modulates macrophage cytokine secretion and phagocytosis in response to poly(lactic-co-glycolic acid) microparticles and filmsElectronic supplementary information (ESI) available. See DOI: 10.1039/c6tb02269c

• Main Authors: Chen, Esther Y, Chu, Shu-Hui, Gov, Lanny, Kim, Yoon Kyung, Lodoen, Melissa B, Tenner, Andrea J, Liu, Wendy F
• Format: Journal Article
• Language: English
• Published: 22.02.2017
• ISSN: 2050-750X; 2050-7518
• DOI: 10.1039/c6tb02269c

Biocompatibility is a major concern for developing biomaterials used in medical devices, tissue engineering and drug delivery. Poly(lactic- co -glycolic acid) (PLGA) is one of the most widely used biodegradable materials, yet still triggers a significant foreign body response that impairs healing. Immune cells including macrophages respond to the implanted biomaterial and mediate the host response, which can eventually lead to device failure. Previously in our laboratory, we found that CD200, an immunomodulatory protein, suppressed macrophage inflammatory activation in vitro and reduced local immune cell infiltration around a biomaterial implant. While in our initial study we used polystyrene as a model material, here we investigate the effect of CD200 on PLGA, a commonly used biomaterial with many potential clinical applications. We fabricated PLGA with varied geometries, modified their surfaces with CD200, and examined macrophage cytokine secretion and phagocytosis. We found that CD200 suppressed secretion of the pro-inflammatory cytokine TNF-α and enhanced secretion of the anti-inflammatory cytokine IL-10, suggesting a role for CD200 in promoting wound healing and tissue remodeling. In addition, we found that CD200 increased phagocytosis in both murine macrophages and human monocytes. Together, these data suggest that modification with CD200 leads to a response that simultaneously prevents inflammation and enhances phagocytosis. This immunomodulatory feature may be used as a strategy to mitigate inflammation or deliver drugs or anti-inflammatory agents targeting macrophages. CD200 modified PLGA surfaces inhibits inflammatory cytokine (TNF-α) secretion, and enhances anti-inflammatory cytokine secretion (IL-10) and phagocytosis by macrophages.